How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Sharing Genomic Data Market
- By Data Source: Clinical Genomic Data, Research Genomic Data, Direct-to-Consumer Genomic Data, Pharmacogenomic Data, Population Genomic Data
- By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Healthcare Providers and Hospitals, Government and Public Health Organizations, Genomic Data Repositories and Consortia
- By Data Sharing Model: Open Access Data Sharing, Controlled Access Data Sharing, Federated Data Sharing, Private Data Sharing
- By Application: Precision Medicine, Drug Discovery and Development, Genetic Disease Research, Population Health Studies, Agrigenomics
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Clinical Genomic Data leads By Data Source at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.168 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.176 →
Full report · locked preview
Everything inside the Sharing Genomic Data Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Data Source 5
End User 5
Data Sharing Model 4
Application 5
Companies profiled
Illumina Inc.
Thermo Fisher Scientific Inc.
Qiagen N.V.
BGI Group
Genomics England
23andMe Inc.
Ancestry.com LLC
Color Genomics Inc.
Invitae Corporation
Helix OpCo Inc.
Nebula Genomics
Fabric Genomics Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Illumina Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Thermo Fisher Scientific Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Qiagen N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →BGI Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Genomics England
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →23andMe Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Ancestry.com LLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Color Genomics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Invitae Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Helix OpCo Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Nebula Genomics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Fabric Genomics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →DNAnexus Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Seven Bridges Genomics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Gene by Gene
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,514M by 2033 · 8.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Clinical Genomic Data47.1
- Research Genomic Data14.7
- Direct-to-Consumer Genomic Data8.9
- Pharmacogenomic Data17.6
- Population Genomic Data11.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$268.6M → $536.2M · 9.0%
Europe$187.2M → $336.5M · 7.6%
Asia Pacific$170.9M → $284.9M · 6.6%
Latin America$105.8M → $218.5M · 9.5%
Middle East and Africa$81.4M → $158.5M · 8.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.012026
8.032027
8.042028
8.042029
8.062030
8.082031
8.082032
8.092033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Illumina Inc.25.7
- Thermo Fisher Scientific Inc.19.6
- Qiagen N.V.7.3
- BGI Group4.4
- Genomics England5.1
- 23andMe Inc.9.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Data Source24.4%
End User17.5%
Data Sharing Model31.1%
Application27.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.9
- Europe21.9
- Asia Pacific18.6
- Latin America14.2
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Illumina Inc. | 98 | 85 | 85 | 97 | 93 | 85 | 91 |
| Thermo Fisher Scientific Inc. | 91 | 71 | 75 | 70 | 69 | 93 | 78 |
| Qiagen N.V. | 66 | 65 | 79 | 75 | 70 | 76 | 72 |
| BGI Group | 76 | 59 | 65 | 67 | 75 | 80 | 70 |
| Genomics England | 57 | 75 | 55 | 63 | 67 | 75 | 65 |
| 23andMe Inc. | 53 | 61 | 60 | 48 | 48 | 62 | 55 |
| Ancestry.com LLC | 43 | 49 | 52 | 62 | 40 | 48 | 49 |
| Color Genomics Inc. | 37 | 36 | 44 | 44 | 58 | 36 | 43 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Illumina Inc.
- Thermo Fisher Scientific Inc.
- Qiagen N.V.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Illumina Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Thermo Fisher Scientific Inc. | ◐ | − | ✓ | ◐ | ◐ | ✓ |
| Qiagen N.V. | ◐ | − | ✓ | ◐ | ◐ | ✓ |
| BGI Group | ◐ | − | − | ✓ | ◐ | ◐ |
| Genomics England | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| 23andMe Inc. | − | ◐ | ◐ | − | − | − |
| Ancestry.com LLC | − | − | − | − | − | − |
| Color Genomics Inc. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Illumina Inc.91
2Thermo Fisher Scientific Inc.78
3Qiagen N.V.72
4BGI Group70
5Genomics England65
623andMe Inc.55
7Ancestry.com LLC49
8Color Genomics Inc.43
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Illumina Inc.Thermo Fisher Scientific Inc.
Challenger2
Strong scale, closing on the leaders.
Qiagen N.V.BGI Group
Contender1
Focused players with pockets of strength.
Genomics England
Niche3
Specialists in a single segment or region.
23andMe Inc.Ancestry.com LLCColor Genomics Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Data Source in North America, then scale across Sharing Genomic Data Market — a $647M beachhead inside a $9.77B market.
Beachhead (SOM)$647Mobtainable near-term
Serviceable (SAM)$3.68Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Clinical Genomic Data
Best fit — highest urgency & budget in Data Source.
Economic buyer78 fit
Research Genomic Data
Strong fit — clear ROI and a fast path to value.
End user69 fit
Direct-to-Consumer Genomic Data
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Data Source in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Data Sharing Model
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales41%
Partner / channel29%
Digital / self-serve21%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Data Source leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Sharing Genomic Data Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified25%
Evaluation14%
Closed-won6%
$13.9KCAC
$59KLTV
4.2:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Sharing Genomic Data Market is a durable-growth opportunity — $7.56B by 2033, compounding at 7.2%.
TAM · 2025$4.32Btoday
TAM · 2033$7.56Bforecast
CAGR7.2%2027–2033
Cumulative$52.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.56BTotal addressable market
SAM$2.70BServiceable available market
SOM$595MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.2% CAGR
Demand compounds through 2033, outpacing GDP across Data Source.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Data Source moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.56BLarge & growingTAM by 2033 at 7.2% CAGR
$2.70BServiceable nowreachable with today’s model
$595MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.89BBear4.7% CAGR
$7.56BBase7.2% CAGR
$9.67BBull9.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Sharing Genomic Data Market — a $9.18B market by 2033. Plan: grow share from 8.2% to 14.9%.
Market size · 2033$9.18Btotal addressable
Market CAGR9.8%2027–2033
Target share14.9%from 8.2% today
Revenue ambition$1.37Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.2% | 14.9% | On track |
| Revenue | $680M | $1.37B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 37.0% | 42.6% | On track |
| Customer retention | 85.0% | 94.3% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Data Source
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Data Source share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $180M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Data Source leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Sharing Genomic Data Market conversation — a $3.39B market you can size, segment and defend in minutes.
Market size · 2033$3.39Btotal opportunity
Growth9.7%CAGR to 2033
Addressable buyers1,394+accounts in scope
Typical ROI4.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Data Source
Goal Grow share in Data Source
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.2×return on cost, year one
< 4 mopayback period
$74K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Illumina Inc.Thermo Fisher Scientific Inc.Qiagen N.V.BGI GroupGenomics England23andMe Inc.Ancestry.com LLCColor Genomics Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Sharing Genomic Data Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Sharing Genomic Data Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Shared Wheelchair Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportShaped Dressings Market
Market size, share, segmentation and regional forecast.
$806M market · 2025 base year
View reportSHANK3 Monoclonal Antibody Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportSHANK3 Antibody Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportShaking Incubators Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportShaking Exercise Platforms Market
Market size, share, segmentation and regional forecast.
$602M market · 2025 base year
View reportShaft Dry Granulators Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportShadowless Surgical Light Market
Market size, share, segmentation and regional forecast.
$741M market · 2025 base year
View reportShadowless Operation Lamps Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportShade Guides Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportShack Hartmann Wavefront Sensor Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportSH3GL2 Antibody Market
Market size, share, segmentation and regional forecast.
$786M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.